Clinical trials: Chronic Rhinosinusitis With Polyposis
Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and…
- Trial name
- NCT07807826
- Testing
- CM512
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）
This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and…
- Trial name
- NCT06930612
- Testing
- CM512
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Keymed Biosciences Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
The primary objectives of the study are: To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic…
- Trial name
- AROMA (NCT04959448)
- Testing
- DUPIXENT®
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 717 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- NCT07519577
- Testing
- CM512
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyposis
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal…
- Trial name
- OPALE (NCT06393946)
- Testing
- Dupilumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Sanofi
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM310, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and…
- Trial name
- NCT05436275
- Testing
- CM310
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Keymed Biosciences Co.Ltd
Rhinosinusitis, Chronic Polyposis
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with…
- Trial name
- NCT01946711
- Testing
- Budesonide
- Where
- 4 sites in Germany
- Volunteers
- 14 people
- Sponsor
- Pari Pharma GmbH